Robert Blum is the President and CEO of Cytokinetics, Inc., a biopharmaceutical company focused on developing muscle biology-directed therapies. Since taking the helm in 2007, Blum has navigated the company through various strategic initiatives and financial decisions. His leadership continues to shape Cytokinetics' mission to improve the healthspan of individuals with cardiovascular and neuromuscular diseases.
Who is the CEO of Cytokinetics?
With a career spanning over two decades at Cytokinetics, Robert Blum has been instrumental in steering the company towards its mission of developing therapies for cardiovascular and neuromuscular diseases. Starting as Vice President of Business Development in 1998, Blum's journey within the company saw him rise through various strategic roles, culminating in his appointment as President and CEO in 2007.
Prior to joining Cytokinetics, Blum held significant positions at COR Therapeutics and Marion Laboratories, Inc., bringing a wealth of experience to his leadership at Cytokinetics.
Work History
- Cytokinetics - President & CEO (2007 - Present)
- Cytokinetics - President (2006 - 2007)
- Cytokinetics - EVP, Business Development (2004 - 2006)
- Cytokinetics - SVP Finance and Business Development and CFO (2001 - 2004)
- Cytokinetics - VP, Finance and Business Development and CFO (1998 - 2001)
- Gamida Cell Ltd. - Chairman Of The Board (2018 - 2023)
- COR Therapeutics - Director, Marketing (1995 - 1998)
- COR Therapeutics - Director, Business Development (1991 - 1995)
- Marion Laboratories, Inc. - Positions of Increasing Responsibility in Sales and Marketing (1985 - 1989)
- Syntex Corporation - Business Planning & New Product Planning (1982 - 1985)
Education History
Robert Blum's educational journey began at The Asheville School, where he studied from 1977 to 1981. He then attended Stanford University, earning a B.A. in Human Biology and Economics between 1981 and 1985. Following his undergraduate studies, Blum pursued an M.B.A. at Harvard Business School, completing the program from 1989 to 1991. This robust academic foundation has significantly contributed to his strategic and leadership capabilities in the biopharmaceutical industry.
When did Robert Blum join Cytokinetics?
Robert Blum joined Cytokinetics in January 1998, marking the beginning of a long and impactful career with the company. He ascended through various strategic roles, ultimately becoming the CEO in January 2007. Over the years, Blum has been a pivotal figure in steering Cytokinetics towards its mission of developing therapies for cardiovascular and neuromuscular diseases. As of 2023, he has been with the company for 25 years, demonstrating a steadfast commitment to advancing muscle biology-directed therapies.